During an FDA panel discussion, the US health secretary prioritised easier routes to market for curative therapies.

A study found no rise in ADHD cases, though some drugs for the disorder are still in shortage amid high demand.

Juvenescence has acquired Ro5 to enhance its AI/machine learning capabilities and improve research and development.

The European Commission (EC) has granted marketing authorisation to Sydnexis for its low-dose atropine formulation SYD-101.

Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the ...

Vividion Therapeutics has secured worldwide rights for developing and commercialising VVD-214, the Werner helicase (WRN) ...

The alert comes amid some patients accessing GLP-1RAs through unregulated channels, where safety information is often not ...

China’s NMPA has approved Akeso's PD-1/CTLA-4 bispecific antibody, cadonilimab, to treat persistent, recurrent or metastatic ...

AI is revolutionizing the pharma supply chain by automating manual tasks, monitoring risks and providing predictive insights.

Digital innovations such as ePRO and eCOA are streamlining clinical trials, boosting participant engagement, and improving ...

Italy’s Axxam and Molecular Health have partnered to identify and validate new therapeutic targets in drug development.

The Phase III trial, conducted by Chinese license partner Ascletis, produced strong results for denifanstat compared to ...